Hybrid Closed-Loop System in LADA Patients: A Randomized Trial

Exclusion Criteria

• •1. The patient has been clearly diagnosed with type 2 diabetes or special types of diabetes.
• •2. The patient has experienced acute diabetic complications within the past 1 month, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc.
• •3. The patient has severe symptoms of hypoglycemia intolerance.
• •4. The patient has skin diseases such as rashes and prurigo, or abnormal coagulation function.
• •5. The patient has diseases related to impaired glucose metabolism, such as uncontrolled hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.
• •6. The patient has comorbid severe liver, kidney, gastrointestinal, hematological, brain, circulatory system diseases, etc.
• •7. The patient has other severe chronic diseases (such as malignant tumors, end-stage organ failure, etc.).
• •8. The patient has impaired consciousness or mental illness, lacks self-control, and cannot express clearly.
• •9. Lactating women, pregnant women, or women who plan to become pregnant during the trial period.
• •10. The patient is currently using or has used glucocorticoids or other drugs that interfere with glucose metabolism within 1 month before screening.
• •11. The patient is allergic to the drugs involved in the clinical diagnosis and treatment plan.
• •12. The patient is currently using other closed-loop systems.
• •13. People who are not suitable for conventional insulin pump treatment and those with contraindications.
• •14. The patient is known or suspected to have an insulin-allergic constitution and is allergic to adhesive tape, insulin pumps, or CGM devices.
• •Other situations where the researcher deems the patient unfit to participate in the clinical trial.